Literature DB >> 26985300

Cathepsin B Inhibitors: Combining Dipeptide Nitriles with an Occluding Loop Recognition Element by Click Chemistry.

Janina Schmitz1, Tianwei Li2, Ulrike Bartz3, Michael Gütschow2.   

Abstract

An active site mapping of human cathepsin B with dipeptide nitrile inhibitors was performed for a combinatorial approach by introducing several points of diversity and stepwise optimizing the inhibitor structure. To address the occluding loop of cathepsin B by a carboxylate moiety, click chemistry to generate linker-connected molecules was applied. Inhibitor 17 exhibited K i values of 41.3 nM, 27.3 nM, or 19.2 nM, depending on the substrate and pH of the assay. Kinetic data were discussed with respect to the conformational selection and induced fit models.

Entities:  

Keywords:  Copper-catalyzed azide−alkyne cycloaddition; cysteine proteases; human cathepsin B; nitrile inhibitors

Year:  2015        PMID: 26985300      PMCID: PMC4789671          DOI: 10.1021/acsmedchemlett.5b00474

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  33 in total

1.  Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro.

Authors:  Ales Premzl; Valentina Zavasnik-Bergant; Vito Turk; Janko Kos
Journal:  Exp Cell Res       Date:  2003-02-15       Impact factor: 3.905

Review 2.  Specialized roles for cysteine cathepsins in health and disease.

Authors:  Jochen Reiser; Brian Adair; Thomas Reinheckel
Journal:  J Clin Invest       Date:  2010-10-01       Impact factor: 14.808

3.  Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro.

Authors:  M Murata; S Miyashita; C Yokoo; M Tamai; K Hanada; K Hatayama; T Towatari; T Nikawa; N Katunuma
Journal:  FEBS Lett       Date:  1991-03-25       Impact factor: 4.124

4.  Aziridinyl peptides as inhibitors of cysteine proteases: effect of a free carboxylic acid function on inhibition.

Authors:  T Schirmeister; M Peric
Journal:  Bioorg Med Chem       Date:  2000-06       Impact factor: 3.641

5.  Active Site Mapping of Human Cathepsin F with Dipeptide Nitrile Inhibitors.

Authors:  Janina Schmitz; Norbert Furtmann; Moritz Ponert; Maxim Frizler; Reik Löser; Ulrike Bartz; Jürgen Bajorath; Michael Gütschow
Journal:  ChemMedChem       Date:  2015-06-26       Impact factor: 3.466

6.  E-64 analogues as inhibitors of cathepsin B. On the role of the absolute configuration of the epoxysuccinyl group.

Authors:  N Schaschke; I Assfalg-Machleidt; W Machleidt; D Turk; L Moroder
Journal:  Bioorg Med Chem       Date:  1997-09       Impact factor: 3.641

7.  L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L.

Authors:  A J Barrett; A A Kembhavi; M A Brown; H Kirschke; C G Knight; M Tamai; K Hanada
Journal:  Biochem J       Date:  1982-01-01       Impact factor: 3.857

8.  Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inhibitors.

Authors:  Jure Borišek; Matej Vizovišek; Piotr Sosnowski; Boris Turk; Dušan Turk; Barbara Mohar; Marjana Novič
Journal:  J Med Chem       Date:  2015-08-26       Impact factor: 7.446

Review 9.  The current stage of cathepsin B inhibitors as potential anticancer agents.

Authors:  Janko Kos; Ana Mitrović; Bojana Mirković
Journal:  Future Med Chem       Date:  2014-07       Impact factor: 3.808

10.  Redox-based inactivation of cysteine cathepsins by compounds containing the 4-aminophenol moiety.

Authors:  Bojana Mirković; Izidor Sosič; Stanislav Gobec; Janko Kos
Journal:  PLoS One       Date:  2011-11-04       Impact factor: 3.240

View more
  4 in total

1.  Addition of 2-(ethylamino)acetonitrile group to nitroxoline results in significantly improved anti-tumor activity in vitro and in vivo.

Authors:  Ana Mitrović; Izidor Sosič; Špela Kos; Urša Lampreht Tratar; Barbara Breznik; Simona Kranjc; Bojana Mirković; Stanislav Gobec; Tamara Lah; Gregor Serša; Janko Kos
Journal:  Oncotarget       Date:  2017-07-17

2.  Cysteine-type cathepsins promote the effector phase of acute cutaneous delayed-type hypersensitivity reactions.

Authors:  Johannes Schwenck; Andreas Maurer; Birgit Fehrenbacher; Roman Mehling; Philipp Knopf; Natalie Mucha; Dennis Haupt; Kerstin Fuchs; Christoph M Griessinger; Daniel Bukala; Julia Holstein; Martin Schaller; Irene Gonzalez Menendez; Kamran Ghoreschi; Leticia Quintanilla-Martinez; Michael Gütschow; Stefan Laufer; Thomas Reinheckel; Martin Röcken; Hubert Kalbacher; Bernd J Pichler; Manfred Kneilling
Journal:  Theranostics       Date:  2019-05-31       Impact factor: 11.556

3.  Modification at the 2'-Position of the 4,5-Series of 2-Deoxystreptamine Aminoglycoside Antibiotics To Resist Aminoglycoside Modifying Enzymes and Increase Ribosomal Target Selectivity.

Authors:  Girish C Sati; Vikram A Sarpe; Takayuki Furukawa; Sujit Mondal; Matilde Mantovani; Sven N Hobbie; Andrea Vasella; Erik C Böttger; David Crich
Journal:  ACS Infect Dis       Date:  2019-09-13       Impact factor: 5.084

4.  Mapping the S1 and S1' subsites of cysteine proteases with new dipeptidyl nitrile inhibitors as trypanocidal agents.

Authors:  Lorenzo Cianni; Carina Lemke; Erik Gilberg; Christian Feldmann; Fabiana Rosini; Fernanda Dos Reis Rocho; Jean F R Ribeiro; Daiane Y Tezuka; Carla D Lopes; Sérgio de Albuquerque; Jürgen Bajorath; Stefan Laufer; Andrei Leitão; Michael Gütschow; Carlos A Montanari
Journal:  PLoS Negl Trop Dis       Date:  2020-03-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.